

Nevada Medicaid

Submit fax request to: 855-455-3303

Please note: All information below is required to process this request.

Nayzilam® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED.

N		•	D •	Landa Carria Carr		
Member Name:	mber Informat	ION (required)		Provider Information (required) Provider Name:		
Insurance ID#:			NPI#:	#: Specialty:		
Date of Birth:			Office Phone:	Office Phone:		
Street Address:			Office Fax:	Office Fax:		
City:	State:	Zip:	Office Street Addres	Office Street Address:		
Phone:			City:	State: Zip:		
		Medication I	nformation (require	d)		
Medication Name	:		Strength:	Dosage Fo	orm:	
			Directions for Use:	irections for Use:		
☐ Check if reque	st is for continuation o	f therapy				
		Clinical Inf	formation (required)			
Select the diag	inosis helow		(required)			
_	nittent seizures					
☐ Other diagnosis:			ICD-10 Code(s):	ICD-10 Code(s):		
Clinical inform						
Is the member	12 years of age or old	ler? □ Yes □ No				
Is the medication	on prescribed by or in	consultation with a ne	eurologist? 🗆 Yes 🕒 No)		
Will the dose re	quested exceed two	sprays per seizure clu	uster, a maximum of one	e episode treatment eve	ery three days, and	
a maximum trea	atment of five episode	es every month? 🛚 Y	′es □ No			
If the request is	for continuation of	therapy, has the men	nber experienced a docu	umented positive clinica	al response to	
Nayzilam® ther	apy? (Attach support	ng documentation to	request)	□ N/A	•	
Are there any other	comments, diagnoses, s	ymptoms, medications tr	ried or failed, and/or any othe	er information the physicia	n feels is important to	
this review?						
Please note:		ed unless all required inform				
		quests please call 1-800-7 r non-urgent requests and f				
	-	- •				

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

FA-169 08/03/2020 Page 1 of 1